MoonLake Immunotherapeutics (MLTX) - What Are Investment Firms Saying About This Stock?

Key Points

• Analyst sentiment is mixed: MoonLake Immunotherapeutics has a consensus “Hold” rating from 14 firms, with nine buys, two holds and three sells. The average 12-month price target is $28.50, although targets range widely, including HC Wainwright’s $50 target.
• Institutional ownership is substantial: Hedge funds and other institutional investors own 93.85% of the company, with several firms significantly increasing their positions during the first quarter.
• The stock remains under pressure: MLTX opened at $11.85, down 4%, versus a 52-week range of $9.36 to $23.29. The clinical-stage biotech reported a quarterly loss of $0.84 per share, though that was better than analysts’ expected $0.91 loss.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has earned a consensus rating of "Hold" from the fourteen research firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $28.50.

MLTX has been the topic of a number of recent research reports. Leerink Partners lifted their price target on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an "outperform" rating in a research note on Wednesday, July 1st. Wall Street Zen lowered shares of MoonLake Immunotherapeutics from a "sell" rating to a "strong sell" rating in a report on Sunday, September 27th. Weiss Ratings upgraded shares of MoonLake Immunotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 21st. Cantor Fitzgerald reissued an "overweight" rating on shares of MoonLake Immunotherapeutics in a report on Wednesday, September 16th. Finally, HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of MoonLake Immunotherapeutics in a report on Monday, October 5th.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC increased its holdings in MoonLake Immunotherapeutics by 64.7% in the first quarter. Janus Henderson Group PLC now owns 3,451,628 shares of the company's stock valued at $64,304,000 after purchasing an additional 1,355,640 shares during the period. Weiss Asset Management LP raised its position in MoonLake Immunotherapeutics by 413.1% during the 1st quarter. Weiss Asset Management LP now owns 1,708,328 shares of the company's stock worth $31,843,000 after purchasing an additional 1,375,367 shares during the last quarter. Candriam S.C.A. lifted its holdings in MoonLake Immunotherapeutics by 509.0% during the 1st quarter. Candriam S.C.A. now owns 818,126 shares of the company's stock worth $15,250,000 after buying an additional 683,797 shares during the period. Bank of America Corp DE lifted its holdings in MoonLake Immunotherapeutics by 5,255.8% during the 1st quarter. Bank of America Corp DE now owns 724,794 shares of the company's stock worth $13,510,000 after buying an additional 711,261 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in MoonLake Immunotherapeutics by 105.8% during the 1st quarter. Renaissance Technologies LLC now owns 276,772 shares of the company's stock worth $5,159,000 after buying an additional 142,300 shares during the period. Institutional investors and hedge funds own 93.85% of the company's stock.

MoonLake Immunotherapeutics Stock Down 4.0%

Shares of MLTX opened at $11.85 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 12.56 and a current ratio of 12.56. MoonLake Immunotherapeutics has a 52 week low of $9.36 and a 52 week high of $23.29. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -3.09 and a beta of 1.08. The stock has a fifty day moving average of $12.92 and a 200-day moving average of $16.48.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.91) by $0.07. As a group, sell-side analysts anticipate that MoonLake Immunotherapeutics will post -3.34 earnings per share for the current fiscal year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases. The company is advancing medicines designed to address conditions in which the immune system contributes to chronic inflammation and tissue damage.

Its lead product candidate is sonelokimab, an investigational Nanobody-based therapy designed to selectively inhibit interleukin-17A and interleukin-17F, two cytokines involved in inflammatory disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.